BTF Best of ASH and SABCS 2024, Houston
The BTF Best of ASH & SABCS 2024, Houston, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.
This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients.
Target Audience
- Hematologists, Oncologists
- Surgeons
- Radiation Oncologists
- Physician Assistants/Nurse Practitioners
- Pharmacists
- Nurses
Organizing Committee
Conference Director:
Binay Shah, MD, MHA - Binaytara Foundation
Co Chairs:
Rachel Layman, MD - MD Anderson Cancer Center
Shilpan Shah, MD - Houston Methodist
Planning Committee
Eleanor Hobaugh, PharmD, BCOP - Houston Methodist
VENUE INFORMATION
A limited number of rooms have been booked at the Hyatt Regency Houston/Galleria for attendees and sponsors of this meeting at a discounted rate of $155/night. Please book your room early to take advantage of the discounted rate. The cut off date is Wednesday, January 3, 2024.
Learning Objectives
- Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.
- Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
- Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
- Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
- Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.
GLOBAL ONCOLOGY PROJECT
To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:
DAY 1 – January 19th, 2024
All times are listed in Central Standard Time (CST)
03:00 PM – 03:55 PM: Registration/Networking & Exhibits
03:55 PM – 04:00 PM: Opening Remarks
04:00 PM – 05:00 PM: Session 1
Moderator: Solange Cox, MD
04:00 PM – 04:20 PM: Radiotherapy – Best Breast Practice - Simona Shaitelman, MD, EdM
04:20 PM – 04:40 PM: Updates in Surgical Approach – Best Breast Practice -Taiwo Adesoye, MD, MPH
04:40 PM – 05:00 PM: Q & A
05:00 PM – 06:30 PM: Session 2 – Case-Based Discussion
Moderator: Lawrence Rice, MD
Case 1 – Bleeding Disorder - Akhil Mehta, DO, MPH
Case 2 – Clotting Disorder - Vahid Afshar-Kharghan, MD
Case 3 – ITP/TTP - Shubham Adroja, MD
Case 4 – Anemia - Ethan Burns, MD
Case 5 – Bone Marrow Failure - Vikram Dhillon, DO, MBA
Panel: Eleanor Hobaugh, PharmD, BCOP
06:30 PM – 07:15 PM: Networking/Reception & Exhibits
DAY 2 – January 20th, 2024
07:00 AM – 07:55 AM: Breakfast & Exhibits
07:55 AM – 08:10 AM: Binaytara Foundation - Binay Shah, MD, MHA
08:10 AM – 09:40 AM: Session 3
Moderators: Shilpan Shah, MD; Martha Mims, MD, PhD
08:10 AM – 08:35 AM: MDS/Acute Leukemia - Martha Mims, MD, PhD
08:35 AM – 09:00 AM: Myeloproliferative Neoplasms and CML - Shilpan Shah, MD
09:00 AM – 09:25 AM: Cellular Therapy in Hematologic Malignancies – Recent Updates - Sai Ravi Pingali, MD
09:25 AM – 09:40 AM: Q & A
09:40 AM – 10:00 AM: Break & Exhibits
10:00 AM – 11:45 AM: Session 4
Moderator: Tejo N. Musunuru, MD
10:00 AM – 10:25 AM: Lymphoma - Sravanti Teegavarapu, MD
10:25 AM – 10:50 AM: Chronic Lymphocytic Leukemia - Alessandra Ferrajoli, MD
10:50 AM – 11:15 AM: Multiple Myeloma - Carrie Yuen, MD
11:15 AM – 11:45 AM: Q & A
11:45 AM – 12:45 PM: Lunch & Exhibits
12:45 PM – 02:30 PM: Session 5
Moderator: Michelina Cairo, MD
12:45 PM – 01:10 PM: Hormone Receptor Positive Breast Cancer - Rachel Layman, MD
01:10 PM – 01:35 PM: HER2 Positive Breast Cancer - Darya Kizub, MD
01:35 PM – 02:00 PM: Triple Negative and HER2 Low Breast Cancer - Akshjot Puri, MD
02:00 PM – 02:30 PM: Q & A
02:30 PM – 03:30 PM: Session 6 – Case-Based Discussion
Moderator: Carlos Barcenas, MD, MSc
Case 1 – DCIS - Ahmed Elkhanany, MD
Case 2 – Inflammatory Breast Cancer - Azadeh Nasrazadani, MD, PhD
Case 3 – Metaplastic Breast Cancer - Polly Niravath, MD
03:30 PM: Adjourn
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Rachel Layman, Rachel M. Layman, MD. Professor, Breast Medical Oncology, MD Anderson Cancer Center
Shilpan Shah
Taiwo Adesoye, MD, MPH
Alessandra Ferrajoli, MD, Professor
Darya Kizub, MD
Martha Mims
Sai Ravi Pingali
Akshjot Puri, MD
Simona Shaitelman
Sravanti Teegavarapu
Carrie Hau Lai Yuen, MD
Shubham Adroja
Vahid Afshar-Kharghan, MD
Ethan Burns, MD
Vikram Dhillon, DO, MBA
Ahmed Elkhanany, MD
Akhil Mehta
Azadeh Nasrazadani, MD PhD
Polly Niravath, MD
Carlos Barcenas, MD, MSc
Michelina Cairo
Solange Cox, MD
Tejo Musunuru, MD
Lawrence Rice
Eleanor Hobaugh, PharmD, BCOP
Available Credit
- 8.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 8.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 8.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.